Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
In Phase 3 SURMOUNT trials, Retatrutide achieved unprecedented 24.2% mean weight loss at the 12mg dose over 48 weeks, with 91% of participants achieving 15% body weight reduction
The alopecia diagnosis is secure
By dampening this system, GLP-1 agonists may break the cycle connecting chronic stress, overeating, and depression
Which Medication Appears More Effective
This is where the evidence becomes particularly compelling and also where the most important caveat applies
MHRA Licensing and the ILAP Route Eli Lilly is expected to submit retatrutide to the MHRA for marketing authorization in late 2026 or early 2027
US$ 26.18
US$ 25.47
US$ 29.71
US$ 20.18
US$ 21.84
US$ 29.28
